Background and Aim: Psoriasis is a common chronic skin disease with high morbidity and economic burden for patients and healthcare system. The goal of this study was to evaluate the impact of age, disease severity, and therapeutic regimen on the quality of life of the patients with psoriasis who were treated with biological drugs.
Methods: This cross-sectional study was conducted on 110 patients suffering from psoriasis whom were admitted to the psoriasis clinic in Razi Hospital, Tehran, Iran in 2015 and 2016. The Persian version of the Dermatology Life Quality Index (DLQI) questionnaire was used to evaluate patients' quality of lives. Using IBM SPSS Statistics (IBM Corp., Armonk, NY, USA) version 22, descriptive and inferential statistics methods were applied to summarize and present the collected data. Chi square test was used for making comparisons.
Results: Seventy-four male patients and 36 female patients were enrolled. The mean age of the participants was 38.8 (range: 18 to 73) years. DLQI scores had a normal distribution and a mean ± standard deviation (SD) equals to 6.51±6.66. The correlations between age and disease severity, quality of life and age, as well as quality of life and disease severity, and quality of life and treatment were not significant (P>0.05).
Conclusion: It seems that the quality of lives of the patients were not affected by the age, severity of the disease, and therapeutic regimen of biological drugs.
